0950 Share Price

Open 6.91 Change Price %
High 6.91 1 Day -0.08 -1.16
Low 6.80 1 Week 0.00 0.00
Close 6.82 1 Month -0.27 -3.81
Volume 16420 1 Year -2.11 -23.63
52 Week High 9.79
52 Week Low 5.08
0950 Important Levels
Resistance 2 6.92
Resistance 1 6.88
Pivot 6.84
Support 1 6.76
Support 2 6.72
HKG HongKong Most Active Stocks
2324 0.06 20.00%
0261 0.01 0.00%
0566 3.91 0.00%
0997 0.04 0.00%
1398 4.85 0.00%
3988 3.60 0.00%
2233 0.89 8.54%
0981 1.03 0.00%
0939 5.88 -0.17%
1051 0.15 7.14%
More..
HKG HongKong Top Gainers Stocks
0711 1.07 50.70%
1137 1.64 33.33%
0524 0.57 23.91%
2324 0.06 20.00%
8286 0.66 15.79%
0559 0.40 14.29%
8155 0.08 14.29%
8106 0.65 14.04%
8249 0.65 14.04%
1039 1.80 12.50%
More..
HKG HongKong Top Losers Stocks
4333 60.00 -25.00%
1176 0.79 -20.20%
8046 0.05 -16.67%
8002 4.00 -15.97%
0607 2.71 -15.05%
8088 0.12 -14.29%
0660 0.08 -11.11%
0200 11.22 -10.38%
8262 1.83 -10.29%
0685 1.16 -10.08%
More..

Lee's Pharmaceutical (HKG: 0950)

0950 Technical Analysis 1.5
As on 9th Dec 2016 0950 Share Price closed @ 6.82 and we RECOMMEND Buy for LONG-TERM with Stoploss of 6.60 & Sell for SHORT-TERM with Stoploss of 6.99 we also expect STOCK to react on Following IMPORTANT LEVELS.
0950 Target for December
1st Target up-side 7.22
2nd Target up-side 7.47
3rd Target up-side 7.73
1st Target down-side 6.48
2nd Target down-side 6.23
3rd Target down-side 5.97
0950 Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.leespharm.com
0950 Address
0950
Bio-Informatics Centre
Unit 110-111
Shatin,
Hong Kong
Phone: 852 2314 1282
Fax: 852 2314 1708
0950 Latest News
Interactive Technical Analysis Chart Lee's Pharmaceutical ( 0950 HKG HongKong )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Lee's Pharmaceutical
0950 Business Profile
Lee’s Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, and sells pharmaceutical products in the People's Republic of China and Hong Kong. It focuses on cardiovascular, dermatology, oncology, gynecology, ophthalmology, and other areas. The company operates through two segments, Proprietary Products and Licensed Products. The Proprietary Products segment manufactures and sells self-development pharmaceutical products, such as Livaracine for the treatment of heart and other cardiovascular diseases; Yallaferon for viral-infected diseases; Slounase for shortening the bleeding time and reducing loss of blood; and Eyprotor for cornea ulcers. The Licensed Products segment trades license-in pharmaceutical products, including Carnitene for the treatment of cardiac diseases; Ferplex for sideropenic anemias; Zanidip for hypertension; Aloxi for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; Dafnegin for candidiasis; and Veloderm for burns and wounds healing. This segment’s license-in pharmaceutical products also comprise Gaslon N for gastric ulcer and gastritis; Brio PTCA balloon catheters for PTCA treatment in cardiovascular disease; Hyalofamme for the treatment of vaginal dryness; Unidrox for the treatment of urinary tract infections and respiratory tract infections; and Levocarnitine oral solution for the treatment of primary and secondary carnitin deficiency. The company, through a collaboration agreement with ScinoPharm Taiwan, Ltd., also develops and produces Fondaparinux, an anti-thrombotic agent; and Travoprost and Bimatoprost, two prostaglandin derivative drugs for treating glaucoma. Lee’s Pharmaceutical Holdings Limited is headquartered in Shatin, Hong Kong.